Posted On: April 17, 2026 by Team Occustar
On January 4, 1987, an Amtrak passenger train traveling at over 100 miles per hour struck a set of Conrail locomotives near Chase, Maryland. Sixteen people died. The NTSB investigation confirmed what investigators suspected: the Conrail crew had been smoking marijuana on the job. The engineer would later admit in a 1993 interview that the drug had distorted his perception of speed, distance, and time. He served four years in prison.
In the aftermath, the Federal Railroad Administration overhauled its drug and alcohol procedures for train crews, and Congress began moving toward broader action across all of transportation. Then, two years later, the Exxon Valdez poured accelerant on the fire.
On March 24, 1989, the supertanker Exxon Valdez departed the port of Valdez, Alaska, loaded with 53 million gallons of crude oil. Just after midnight, it struck Bligh Reef in Prince William Sound. Eleven million gallons of oil poured into one of North America’s most ecologically pristine stretches of water, eventually coating more than 1,300 miles of Alaskan coastline and killing an estimated 250,000 seabirds, thousands of sea otters, and hundreds of seals and bald eagles. The economic toll on fishing communities was catastrophic and lingered for years.
Investigators found that the captain, Joseph Hazelwood, had been drinking before taking command. Witnesses placed him at Valdez waterfront bars for hours before departure. While Hazelwood was ultimately acquitted of operating the vessel while intoxicated — the blood samples taken hours after the grounding were legally compromised — the narrative was fixed in the public mind. A 1994 jury awarded $5 billion in punitive damages, a figure eventually reduced to $507 million following two decades of appeals and a 2008 Supreme Court ruling that set a landmark precedent limiting punitive damages in maritime cases to a 1:1 ratio with compensatory damages.
The Valdez gave Congress a second inescapable data point: alongside a marijuana-impaired train crew, now an alcohol-impaired tanker captain. Two industries, two substances, two disasters. The case for mandatory impairment testing across all of transportation was no longer debatable.
In 1991, Congress passed the Omnibus Transportation Employee Testing Act, requiring mandatory drug and alcohol testing for employees in safety-sensitive roles across every DOT-regulated industry: trucking, aviation, rail, transit, and pipeline. The Substance Abuse and Mental Health Services Administration (SAMHSA) was established the following year to develop and maintain the scientific standards governing how federal workplace testing is conducted.
That legal and regulatory structure remains the foundation of DOT drug and alcohol testing today.
The mechanics of DOT drug testing are governed by 49 CFR Part 40, administered by the DOT’s Office of Drug and Alcohol Policy and Compliance. Part 40 is not a set of general guidelines — it is a comprehensive regulatory framework that establishes exactly how testing must be conducted, who can conduct it, how results are reported and verified, and what happens when someone tests positive.
Part 40 applies across all DOT modal agencies: FMCSA (trucking and bus), FAA (aviation), FRA (railroad), FTA (transit), and PHMSA (pipeline). Each agency has its own supplemental rules governing when testing is required — pre-employment, random, post-accident, reasonable suspicion, and return-to-duty — but the specimen collection, laboratory analysis, and Medical Review Officer verification process are governed uniformly by Part 40 regardless of industry.
The DOT drug testing panel tests for five categories of substances. These drugs appear on the panel because they are classified under Schedule I or Schedule II of the Controlled Substances Act — substances the federal government has determined either have no accepted medical use, or carry a high potential for abuse even with recognized medical applications.
Marijuana (THC metabolites). Cannabis remains a Schedule I controlled substance under federal law. State legalization — recreational or medical — has no bearing on DOT testing. A driver who tests positive in a state where marijuana is fully legal has still committed a federal violation. This is the most common source of confusion among commercial drivers, and it continues to produce positive results at rates that have kept the industry’s random testing rate elevated for six consecutive years.
Cocaine. A Schedule II substance, meaning it carries recognized medical applications — most notably as a topical anesthetic in certain dental and ENT surgical procedures. When a Medical Review Officer reviews a positive cocaine result, part of that evaluation involves determining whether the result is consistent with illicit use. The metabolite the test identifies — benzoylecgonine — is produced through ingestion or inhalation, not through topical medical application. In rare, well-documented clinical cases, an MRO may report a verified negative. The MRO’s role is not to excuse the result but to evaluate it properly against the evidence.
Amphetamines. This category covers amphetamine, methamphetamine, MDMA, and MDA. Many prescription medications contain amphetamine compounds, and the MRO will consider a valid prescription as part of the review. However, a prescription does not automatically resolve the result — and it does not address the separate question of whether the employee is medically qualified to perform safety-sensitive duties while on that medication.
Opiates. The panel tests for codeine, morphine, and heroin (via the metabolite 6-acetylmorphine). These are among the most tightly controlled substances in medicine, and positive results require careful MRO review. As part of the pending fentanyl rulemaking discussed below, DOT has also proposed adjusting the morphine confirmation cutoff threshold — a technical refinement intended to improve accuracy and reduce unnecessary clinical follow-up.
Phencyclidine (PCP). A hallucinogen with no accepted medical use. Positive results are relatively rare but PCP remains on the panel given its severe impairment profile.
Employers operating under DOT jurisdiction cannot modify the testing panel — not to add drugs, and not to remove them. This is one of the most common compliance misunderstandings in the industry.
An employer who wants to test for additional substances — fentanyl ahead of the final rule, benzodiazepines, synthetic cannabinoids — must conduct a separate, non-federally mandated test and keep those results entirely apart from the DOT-regulated program. Combining the two creates serious compliance exposure. The five-panel structure is set at the federal level, and it applies identically to every covered employer in every covered industry.
The FMCSA Drug and Alcohol Clearinghouse — a federal database tracking violations among CDL and commercial learner’s permit holders — has provided a real-time national picture of positive test rates since its launch in January 2020. That picture is not reassuring.
As of early 2026, more than 190,000 CDL drivers carry a prohibited status in the Clearinghouse — roughly one in every 30 CDL holders in the system. Positive drug tests account for approximately 82% of all violations reported. Marijuana metabolites represent roughly 60% of all positive drug test results. Since the Clearinghouse launched, more than 206,000 marijuana-related positives have been recorded.
It is important to note that the Clearinghouse is an FMCSA-specific system, covering CDL and CLP holders subject to FMCSA drug and alcohol testing rules. Pilots, railroad workers, pipeline operators, and transit employees are not tracked in this database — each modal agency manages its own testing data. The Clearinghouse numbers reflect trucking, but they are the most comprehensive real-time dataset available and they tell a consistent story: the problem has not improved.
FMCSA’s random controlled-substances testing rate has remained at 50% for 2026 — the sixth consecutive year at that level since the agency raised it from 25% in 2020. DOT announced the unchanged rate on January 8, 2026. The rate is tied directly to industry-wide positive testing data, and the data has not supported a reduction.
The Clearinghouse-II update, which took full effect on November 18, 2024, significantly strengthened the system’s enforcement reach. Under Clearinghouse-II, state driver licensing agencies (SDLAs) are required to downgrade or deny a CDL or CLP whenever a driver carries a prohibited status in the Clearinghouse. The commercial driving privilege is removed until the driver completes the full return-to-duty process — SAP evaluation, recommended treatment or education, a negative return-to-duty test, and a follow-up testing plan.
Drivers cannot sidestep this by moving between carriers. The violation follows them in real time. As of early 2026, more than 148,000 prohibited drivers had not yet initiated the return-to-duty process. For employers, the compliance obligation is clear: query the Clearinghouse before every hire, run annual queries on all active drivers, and report violations within required timeframes. Clearinghouse-related failures consistently rank among the top FMCSA audit findings.
The most significant near-term change to the DOT drug testing panel involves fentanyl. On September 2, 2025, DOT published a Notice of Proposed Rulemaking (NPRM) in the Federal Register (90 FR 42363) proposing to add fentanyl and its primary metabolite norfentanyl to the testing panel. The public comment period closed October 17, 2025, and legal observers expect a final rule in early 2026.
The pathway follows a defined statutory process. Under the Omnibus Transportation Employee Testing Act of 1991, DOT is required to align its drug testing panel with the HHS Mandatory Guidelines for Federal Workplace Drug Testing Programs. HHS formally added fentanyl and norfentanyl to its authorized testing panels on January 16, 2025 (90 FR 4662). DOT’s NPRM is the conforming step.
The rationale is straightforward. Fentanyl is responsible for approximately 70% of all U.S. drug overdose deaths. Roughly 150 Americans die from fentanyl-related overdoses every day. The current five-panel test does not detect fentanyl — a gap that is increasingly difficult to justify given the scale of the crisis and fentanyl’s growing presence as a standalone illicit substance rather than just a heroin adulterant.
Employers should begin preparing now. When the final rule takes effect, drug and alcohol testing policies will require revision. Coordinate with your C/TPA, MRO, and laboratory contacts ahead of the change.
On December 18, 2025, President Trump signed an Executive Order directing the Attorney General to expedite the formal rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act. This generated considerable attention — and considerable confusion about what it actually means for DOT-regulated employers.
The short answer: nothing has changed yet, and your testing obligations are unchanged.
The Executive Order does not reschedule marijuana. It directs the Department of Justice to complete the rulemaking process that was already underway following a DOJ proposed rule published in May 2024. Formal rescheduling requires agency rulemaking, public comment, and final rule publication. As of this writing, no final DEA rescheduling rule has taken effect. Marijuana remains a Schedule I controlled substance, and DOT testing requirements remain fully in place.
The longer-term picture is genuinely uncertain. The HHS Mandatory Guidelines — which DOT is required by law to follow — currently authorize testing for Schedule I and Schedule II substances. If marijuana moves to Schedule III, that statutory footing becomes more complicated, and some legal observers have raised questions about whether DOT’s testing authority would require an explicit Congressional or regulatory carve-out to survive. DOT is aware of the issue. The transportation safety community is watching closely.
Until formal rescheduling is finalized and DOT issues updated guidance through proper regulatory channels, the compliance posture for every covered employer is exactly what it was before the executive order: test as required, enforce your policies, and document everything. Do not allow confusion about future regulatory changes to create current compliance gaps.
DOT drug testing exists because people died. The five-panel structure, the MRO verification system, the random testing requirements, the Clearinghouse — all of it traces back to a marijuana-impaired crew ignoring a stop signal at 108 miles per hour, and an alcohol-impaired captain who should never have been on the bridge. Decades of regulatory refinement have built something that, for all its complexity, has a clear and serious purpose.
That purpose is becoming more rigorous, not less. Fentanyl is approaching the panel. Clearinghouse enforcement is fully operational and increasingly automated. The marijuana policy environment is the most unsettled it has been since the program began. Employers who stay current and keep their programs tight are not just checking a compliance box — they are part of the reason the system works.
A compliance program that was current six months ago may already need review. Before anything else changes, verify the following:
Questions about your testing program? OccuStar’s team of DOT compliance specialists is available to review your program and ensure it meets current federal requirements.